INOTREM
23.6.2021 08:02:27 CEST | Business Wire | Press release
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that it has filed a patent to protect a new therapeutic modality against TREM-1, a monoclonal antibody.
The filing of this monoclonal antibody patent is a significant milestone for Inotrem’s strategic development as it represents the company’s second asset, next to nangibotide, and a further diversification of its drug portfolio. Moreover, by modulating the activity of the TREM-1 pathway over extended periods of time, this therapeutic modality offers a new and promising alternative for the treatment of chronic inflammatory diseases.
TREM-1 is an immunoreceptor initially discovered for its role in the pathophysiology of acute inflammatory syndromes and in particular septic shock. Since its inception in 2013, Inotrem has introduced the therapeutic peptide nangibotide into the clinics for acute inflammatory syndromes secondary to severe infections. Two Phase IIB clinical trials are currently ongoing in septic shock and COVID-19 patients. Since its discovery in 2000, an increasing number of research work indicated the implication of the therapeutic target TREM-1 in not only acute inflammatory diseases but also in the development of chronic inflammation. Pioneering these approaches, Inotrem initiated in 2019 a proprietary research and discovery program to identify a new modality against TREM-1 in the form of a therapeutic monoclonal antibody, with pharmacological properties suitable for the management of chronic indications.
“Inotrem’s research team’s exceptional commitment is at the core of today’s success. Adding a monoclonal antibody to our therapeutic modalities targeting the TREM-1 pathway now allows us to expand our development efforts beyond the current acute indications to also address chronic inflammatory syndromes with a high unmet medical need,” said Marc Derive, co-founder and Chief Scientific Officer of Inotrem.
“Today’s announcement constitutes a key advancement for Inotrem. This new patent application demonstrates the company’s ability to deploy its vision and strategy. Through its proprietary technology platform addressing inflammatory diseases, it has the potential to develop treatments in a wide number of inflammatory indications, both acute and now chronic, for which there are today no or limited specific treatment. We are looking forward to the clinical development progress of this new asset, with preclinical development slated to start later this year,” said Jean-Jacques Garaud, Executive Vice-President, Head of Scientific and Medical Affairs and Inotrem’s co-founder.
Chronic inflammatory diseases are inflammatory-driven diseases of the digestive system, joints, skin, respiratory system, kidneys, and various other organs. Most of them have no cure, and new biologics have recently reached the market to target inflammation. But there are still a high number of non-responders to these innovative drugs, and therefore a very significant unmet medical need.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapy for inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and COVID-19. In parallel, Inotrem has launched a program to develop new therapeutic modalities targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors. For more information please visit: www.inotrem.com
About TREM-1 pathway
TREM-1 pathway is an amplification loop of the immune response that triggers an exuberant and hyperactivated immune state which is known to play a crucial role in the pathophysiology of septic shock and acute myocardial infarction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005982/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Begins Mass Production of PM1763 SSD Optimized for Next-Generation AI Infrastructure8.7.2026 09:30:00 CEST | Press release
PCIe 6.0-based enterprise SSD delivers outstanding performance and enhanced power efficiency for AI and HPC servers9th-generation V-NAND, 4nm controller and liquid-cooling optimization support demanding AI workloads Samsung Electronics Co., Ltd., a global leader in advanced memory technology, today announced mass production of PM1763, the company’s PCIe® 6.0-based enterprise solid state drive (SSD) optimized for next-generation AI and HPC server environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708516273/en/ Samsung Begins Mass Production of PM1763 SSD Optimized for Next-Generation AI Infrastructure As the volume of data required for AI training and inference continues to grow rapidly, enterprise SSDs (eSSDs) capable of delivering data quickly and reliably are becoming increasingly essential to AI infrastructure. Featuring high-speed data transfer and an optimized controller architecture, PM1763 is expected to
FPT Releases Global Study on Scaling Enterprise AI, Highlighting the Shift from Pilots to Platform-Driven Transformation8.7.2026 09:08:00 CEST | Press release
As artificial intelligence moves from experimentation into the core of enterprise operations, a new reality is emerging: scaling AI is no longer a technology challenge, but a transformation imperative. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708088519/en/ FPT Corporation today announced the release of a global thought leadership study, titled “From Pilots to Reusable Platforms: A Blueprint for Scaling Enterprise AI.” Published on 08 July 2026, this is a commissioned study conducted by Forrester Consulting on behalf of FPT, examining how enterprises across regions and industries are advancing their AI journeys - and why many remain unable to translate early momentum into consistent, enterprise-wide impact. The executive study is based on a global survey of 397 business and technology decision-makers globally, supported by in-depth interviews with senior executives across North America, Europe, Asia Pacific and Japan
Rubrik Security Cloud Launches on the AWS European Sovereign Cloud8.7.2026 09:00:00 CEST | Press release
The launch will allow highly regulated European Union organisations to meet strict EU data residency requirements Rubrik, the Security and AI Operations Company, today announced the availability of Rubrik Security Cloud on the AWS European Sovereign Cloud, providing the European Union (EU) public sector and highly regulated private organisations with a cloud-native path for sovereign cyber resilience. Organisations increasingly require resilience measures that are sovereign, not just contractually compliant. Rubrik Security Cloud on the AWS European Sovereign Cloud meets this demand. It will allow highly regulated industries, such as banking, utilities, healthcare, and government, to leverage the full power of AWS, while meeting stringent data residency requirements within the European Union (EU). Advanced security features on a fully featured, independently operated sovereign cloud The AWS European Sovereign Cloud is a fully featured, independently operated sovereign cloud backed by s
Wolters Kluwer Brings Libra AI Workflows Into One for Italian Legal Professionals8.7.2026 09:00:00 CEST | Press release
Building on Libra by Wolters Kluwer’s early leadership, strong market momentum and advanced AI innovation in Italy, its capabilities are now directly available in One via the Libra add-in. Wolters Kluwer Legal & Regulatory today announced the integration of Libra by Wolters Kluwer AI workflows in One, its leading legal research platform in Italy. This step further reinforces the strong commercial success and rapid market adoption of the Libra legal AI workspace in the country. With the integration generative AI features are directly available in the research workflow of legal professionals allowing a seamless experience without switching between tools. The integration follows the launch of the Libra legal AI workspace in Italy in February, setting a new benchmark for AI-enabled legal research by combining advanced AI capabilities with authoritative and trusted legal content from One and supporting lawyers across their full workflow, from research to analysis and document drafting. With
Flix and Klarna Expand Partnership to Give Millions of Travelers Across the U.S. and Europe More Ways to Pay8.7.2026 09:00:00 CEST | Press release
Flix and Klarna, the global digital bank and flexible payments provider, today announced an expanded partnership that brings more flexible payment options to millions of travelers across its platforms. Beginning today, Klarna will be available in 21 Flix markets, adding the UK, Germany, Italy, France, Poland, Switzerland, Austria, and Spain, among others, to its existing presence in the U.S. and Sweden. With Klarna now embedded directly into the Flix booking flow, passengers have three new ways to pay: in full at the time of booking, in interest-free installments, or through longer-term financing for larger purchases. For cross-border journeys, Klarna removes foreign exchange fees, letting travelers pay in their local currency with no hidden conversion costs. Klarna users will also receive exclusive deals when booking through Flix platforms. "Travel is one of the biggest spending categories in people's lives, yet flexibility at checkout has lagged behind,” said David Sykes, Chief Comme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom